Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2011; 17(44): 4858-4866
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4858
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4858
Figure 5 Effect of erlotinib in an animal model of colitis-associated dysplasia on mitogen-activated protein kinase components.
Samples from (A) proximal, (B) mid, and (C) distal regions of normal rats and trinitrobenzene sulfonic acid (TNBS) + vehicle and TNBS + erlotinib treated animals were ground, and equal amounts of protein (30 μg) were separated by sodium dodecyl sulfate 12%-polyacrylamide gel electrophoresis before analysis by Western blotting. Antibodies against pErk1/2 and Erk1/2 were used. Lines are representative samples of 3 independent rats per group. Densitometry was performed by ImageQuant 5.2 Software (Typhoon 9410) (n = 10-20 ± SEM).
- Citation: Pagán B, Isidro AA, Cruz ML, Ren Y, Coppola D, Wu J, Appleyard CB. Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World J Gastroenterol 2011; 17(44): 4858-4866
- URL: https://www.wjgnet.com/1007-9327/full/v17/i44/4858.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i44.4858